Skip to content

Total debt at other companies

Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1.99M-20.1%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$2.89M-9.5%
Savara logo
SavaraSVRA
$30.07M+1.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$13.61K-99.9%
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $1.11M.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s total debt?
Upstream Bio, Inc. (UPB) reported total debt of $1.11M in Q1 2026.
How has Upstream Bio, Inc.'s total debt changed year-over-year?
Upstream Bio, Inc.'s total debt decreased by 34.5% year-over-year, from $1.7M to $1.11M.
What is the long-term trend for Upstream Bio, Inc.'s total debt?
Over 2 years (2023 to 2025), Upstream Bio, Inc.'s total debt has grown at a 431.0% compound annual growth rate (CAGR), from $45K to $1.27M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.